Sixteen acceptably randomized studies of anticoagulant therapy after cerebral or retinal ischemia or infarction are reviewed and the results among 1,046 anticoagulated patients and 1,071 controls are analyzed. The following conclusions are derived. 1) Anticoagulant therapy has not been shown to be better than control management after transient ischemia or nonprogressing ischemic stroke; this is true whether the control management was deliberately ineffectual treatment (generally studies completed in 1974 or earlier) or platelet antiaggregant therapy (pooled results of three recent studies). 2) Although a study done 30 years ago demonstrated no benefit, a recent study showed benefit from anticoagulant therapy in patients who had had cerebral emboli of cardiac origin; additional controlled data are needed. 3) There is evidence that patients with thrombosis in evolution might benefit from anticoagulant therapy; additional controlled data are needed. (Table 1) .
D oes anticoagulant therapy (ACT) improve
stroke and death outcomes in patients who have suffered ischemia or infarction of the brain or retina? I review 17 controlled studies'- 21 on the subject (Table 1) .
Materials and Methods
Studies were found through computerized search, direct search of the cumulative Index Medicus, suggestions from colleagues, and review of references in articles already discovered. Being well aware that an analysis such as this, especially when the work of one person, can suffer from error, incompleteness, and bias, 22 I solicit references to studies I have missed and alternative interpretations of the data I have summarized. I will, on request, provide more extensive notes on my own interpretations, as well as the various calculations.
Where possible, I have used the end points of stroke or death (S + D) occurring during observation. The overall expected S + D per patient-month of observation for a given (arm of a) study is the sum of S + D for the treated and control groups divided by the sum of the patient-months for the two groups. This overall expected S + D rate multiplied by the patient-months of observation for each group separately gives the expected S + D for each group. Significance is defined as /?<0.05.
Where feasible, I have pooled the S + D results for meta-analysis. Certain studies present results in forms not suitable for S + D analysis and are therefore not amenable to meta-analytic pooling; the authors' end points are given for these studies and the authors' analyses of significance are recorded. Table 2 summarizes the S + D results from 10 studies in which patients with stroke and transient ischemic attacks (TIAs) were randomized to ACT or to deliberately ineffectual treatment (placebo, no treatment, or deliberately ineffectual doses of anticoagulants). Among 20 identifiable groups or subgroups from these 10 studies there is one (the Cerebral Embolism Study 20 ) in which the ACT outcome was significantly better than control. In three other instances (the completed stroke and embolism groups from the National Cooperative Study 910 and the male stroke group from the Veterans Administration Cooperative Study") the ACT results were significantly worse than control. In the other 16 groups or subgroups the difference between the ACT and control outcomes was not significant (in seven the ACT outcomes were a bit better, and in nine a bit worse, than control). Table 3 summarizes the results from three studies of ACT versus platelet antiaggregant therapy. ACT gave slightly better results in two and slightly worse results in the third study; in no study was the difference significant. ICA, internal carotid artery territory; MCA, middle cerebral artery territory; ACA, anterior cerebral artery territory; VB, vertebrobasilar artery territory; TIA, transient ischemic attack; RIND, reversible ischemic neurologic deficit.
Results

Individual Studies
Of the 17 studies in Table 1 , three presented data in forms that do not permit S + D analysis. The authors' conclusions are summarized in the text, along with additional results of Duke et al, 21 whose S + D results are given in Table 2 .
Marshall and Shaw 1 -2 randomized 25 acute stroke patients to ACT and 26 to control management. ACT was gradually withdrawn after 21 days. By 6 weeks there had been six deaths in the ACT group and three deaths plus three ischemic episodes among the controls. By 6 months there had been another six deaths (two in the ACT group) and another three ischemic episodes (all in the ACT group). Whether the five ischemic episodes were TIAs or strokes is not stated; S + D analysis therefore cannot be performed. Marshall and Shaw analyzed survival to 6 weeks; they found ACT "not of value." Carter 3 -4 assigned by alternation to ACT or to control management 76 patients who had had a stroke within the 48 hours preceding entry and who had shown progression for at least 2 hours before or after admission to the hospital. ACT was given for 1 month ACT, anticoagulant therapy; C, control; >, better than; <, worse than; NS, difference not significant; TIA, transient ischemic attack; RIND, reversible ischemic neurologic deficit.
•"Includes TIA with incomplete recovery.
and then tapered off. All patients were followed until 6 months, when outcome was assessed for two subgroups. Among the 22 ACT patients whose deficits were "incomplete but progressing" when treatment was begun, 17 recovered or improved and five were unimproved or had died; among the 20 similar controls the division was 10 and 10 (p<0.05). Among 16 ACT patients whose deficits were "clinically complete when treatment was begun" nine recovered or improved and seven were unimproved or had died; the division was nine and nine among 18 similar controls (p>0.05). Since the numbers of S + D are not given, S + D analysis cannot be performed. Wallace 13 randomized 52 patients who had had a thrombosis at least 14 days before entry and who had "lasting evidence of neurologic deficit" (51 cerebral, one brainstem), 27 to ACT and 25 to control management. Mean follow-up was 9.5 months for the ACT group (time spent on ACT is not given) and 10 months for the controls. There were three strokes in the ACT group and 10 among the controls. According to Wallace, p was <0.05 for this favorable ACT result. There were five or six ACT and seven or eight control deaths. It was not stated whether any death accompanied or followed any of the 13 strokes; therefore, these data are not suitable for S + D analysis.
Duke et al 21 randomized 112 patients with acute but stable and nonprogressing partial stroke to 7 days of continuous intravenous heparin therapy (activated partial thromboplastin time maintained between 50 and 70 seconds) (ACT) and 113 patients to 7 days of intravenous placebo treatment (control). At 0.25, 3, and 12 months (no mention was made of therapies that might have been given during the year of follow-up) there was no difference between the two groups in daily activity level. By 12 months there was an excess of deaths in the heparin group (17 vs. 8 among the controls); the authors' life table analysis gives p<0.01 for this undesirable ACT outcome. Since stroke data are not given for the later follow-up periods, S + D analysis for these periods is not possible.
Thus, among the five results (two from Carter) not suitable for S + D analysis, two were significantly favorable and one was significantly unfavorable for ACT. Combining these results for variously defined outcomes with the S + D outcomes listed in Tables 2 and 3 , there are three significantly favorable and four significantly unfavorable results among 1,046 ACT patients and 1,071 controls from 27 groups and subgroups of 16 randomized studies.
The results of Thygesen et al 12 (ACT worse but not significantly so) have not been included in the above discussion because Thygesen et al did not explicitly state that their patients were randomized.
Pooled Results
In addition to reviewing results in the individual cohorts, one can also look at pooled S + D results. Table 2 shows that 714 ACT patients did significantly worse than 723 controls who received deliberately ineffectual treatment. Table 3 shows no significant benefit of ACT in 128 patients compared with 132 controls who received aspirin + dipyridamole (ASA + DP). The addition of a third study (114 ACT patients, 127 controls who received ASA) to the pool on the assumption that the use of ASA + DP resulted in a response no different from that seen with ASA alone does not change the result of the original pooling. Table 2 also summarizes outcome by sex. Outcome was worse among 199 men on ACT than among 206 men on deliberately ineffectual treatment (p<0.02). Outcome was slightly worse among 43 treated women than among 39 control women (p>0.05). Table 2 also summarizes outcome by type and stability of ischemic event: TIA; TIA or minor stroke (the minor stroke cases of Bradshaw and Brennan 16 cannot be separated from their TIA cases); embolism; stable stroke; and all strokes thrombotic 5 Baker et al, 6 Hill et al, 7 -8 National Cooperative Study, 910 Veterans Administration Cooperative Study," Enger and Boyesen, 14 Pearce et al, 15 Bradshaw and Brennan. 16 Studies begun in 1974 or later: Buren and Ygge, 17 Olsson et al, 18 Garde et al, 19 Cerebral Embolism Study, 20 Duke et al. 21 ACT, anticoagulant therapy; C, control; <, worse than; >, better than; NS, difference not significant. or embolic, stable or evolving. For each type of ischemic event ACT gives results no better than control; for all strokes ACT is significantly worse (whether the results of Enger and Boyesen, 14 who do not separate their three TIA case outcomes from their 97 stroke case outcomes, are included or not). Table 4 shows that results of ACT in studies completed in 1974 or earlier were unfavorable (/?<0.02). For studies begun in 1974 or later, no significant advantage from ACT was demonstrable.
Other Table 2 also gives data for acute but stable partial stroke (Duke et al, 21 no benefit from ACT) and for thrombosis in evolution (National Cooperative Study, 910 suggesting that a larger series might have demonstrated ACT to be valuable). In this regard it should be recalled that Carter 34 had noted a significant benefit from ACT in a recovery-improvementdeath analysis in incomplete but progressing stroke. For stable stroke it should be recalled that the studies not suited for pooling showed varying results by a variety of outcome criteria: worsening, Duke et al 21 ; benefit, Wallace 13 ; or no significant difference, Marshall Table 2 also summarizes outcome during 23 months of ACT versus outcome when 15 months of post-ACT follow-up were added (Enger and Boyesen 14 ) . Neither analysis demonstrates benefit. It should be recalled that the patients of Duke et al 21 received no S + D benefit during 1 week of ACT; at 1 year their death rate was worse than control, and their activity level was no better.
Discussion
There is no evidence of significant benefit from ACT in various poolings of patients with brain or retinal ischemia or infarction. With respect to individual studies, in four groups the results were significantly unfavorable. In three groups, however, significant benefit occurred; these are discussed below.
Wallace 13 noted a significantly lower occurrence of new stroke among 27 stroke patients with persisting deficits who were treated with ACT than among 25 controls. However, this suggestion of benefit in a small study is strongly negated by the much heavier evidence of a lack of S + D benefit among the stable stroke patients (330 ACT, 335 control) of four studies pooled in Table 2 . Carter 3 -4 showed a significant benefit from ACT among patients with thrombosis in evolution in a nonpoolable study. The National Cooperative Study 910 showed a nonsignificantly better result among ACT than among control patients with thrombosis in evolution. On the basis of these two outcomes, one could suggest that additional controlled study of stroke in evolution is warranted.
The Cerebral Embolism Study 20 of 1981-1982 showed significant benefit from ACT. However, a contrary result was seen in the embolism arm of the National Cooperative Study 910 of 1957-1961: the ACT outcome was significantly bad. Could the disparity between these two outcomes be due to intracranial hemorrhage among the earlier patients? In this regard the Cerebral Embolism Study had two possible advantages: computed tomography to rule out intracerebral hemorrhage before treatment and the availability of effective antihypertensive therapy to minimize the chance of such hemorrhage during treatment (the National Cooperative Study did not exclude hypertensive patients and the Cerebral Embolism Study excluded only those with blood pressures of >180/115 mm Hg; see Table 1 ). Table 5 attempts to evaluate the possible contribution of intracerebral hemorrhage to the outcome of the earlier study. Although Baker et al 9 and Fisher 10 considered all observed strokes to have been infarcts, only nonstroke deaths are used as ACT end points to eliminate the chance that some end-point strokes might actually have been unrecognized hemorrhages. Despite this adjustment, which is very generous to ACT, significant benefit from ACT cannot be demonstrated in the 1957-1961 cohort or in the pooling of this cohort with the 1981-1982 patients. Still, the finding of apparent benefit from ACT after cardiogenous cerebral embolism in the Cerebral Embolism Study warrants careful attention; further controlled investigation is needed.
With regard to the issue of avoiding intracerebral hemorrhage regardless of the cause of the presenting ischemic event, it can be presumed that effective antihypertensive treatment was available to the patients of Duke et al 21 and the three studies in which the controls received aspirin 17 
-
19 since all four studies were begun in 1974 or later. Furthermore, all patients of Duke et al 21 and some patients of Garde et al 18 and Olsson et al 19 had computed tomograms (see Table 1 ). Nevertheless, these studies did not demonstrate a benefit from ACT. Thus, while it is possible that the unfavorable results of the older studies (Table 4 ) reflected in part the existence or occurrence of intracerebral hemorrhages avoidable now, there is no demonstration from the more recent pooled results that ACT currently offers an advantage over placebo or platelet antiaggregant treatment.
